Grey Wolf Therapeutics

Grey Wolf Therapeutics (Greywolf Therapeutics) is a clinical-stage biotechnology company developing a new therapeutic class of immunotherapies through antigen modulation, aimed at treating people living with cancers and autoimmune disorders. Its approach modulates antigen presentation on cell surfaces so T cells can correctly recognize and target diseased cells, and it is pioneering modulation of Signal 1 in the T cell activation cascade. Lead assets include GRWD5769, a first-in-class oral ERAP1 inhibitor for oncology in Phase 1/2 trials, and GRWD0715, an autoimmunity-focused asset also in Phase 1/2. Backed by Canaan Partners, the company was added to the API Evangelist network as a venture-portfolio company profile. It is a corporate/scientific organization and publishes no public developer API, OpenAPI, SDK, or developer portal.

Grey Wolf Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Immuno-oncology, and Immunotherapy.

Grey Wolf Therapeutics’ developer surface includes engineering blog, support, and 3 more developer resources.

🌐 Visit website 📡 Source on GitHub

10.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyPharmaceuticalsImmuno-oncologyImmunotherapyAntigen ModulationERAP1AutoimmuneOncologyClinical Stage

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 10.2/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 2.1 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/grey-wolf-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 2

The organization behind the API

Website

Website

Blog

Blog

Source (apis.yml)

aid: grey-wolf-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/grey-wolf-therapeutics.png
name: Grey Wolf Therapeutics
description: Grey Wolf Therapeutics (Greywolf Therapeutics) is a clinical-stage biotechnology company developing a new therapeutic
  class of immunotherapies through antigen modulation, aimed at treating people living with cancers and autoimmune disorders.
  Its approach modulates antigen presentation on cell surfaces so T cells can correctly recognize and target diseased cells,
  and it is pioneering modulation of Signal 1 in the T cell activation cascade. Lead assets include GRWD5769, a first-in-class
  oral ERAP1 inhibitor for oncology in Phase 1/2 trials, and GRWD0715, an autoimmunity-focused asset also in Phase 1/2. Backed
  by Canaan Partners, the company was added to the API Evangelist network as a venture-portfolio company profile. It is a
  corporate/scientific organization and publishes no public developer API, OpenAPI, SDK, or developer portal.
url: https://raw.githubusercontent.com/api-evangelist/grey-wolf-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Immuno-oncology
- Immunotherapy
- Antigen Modulation
- ERAP1
- Autoimmune
- Oncology
- Clinical Stage
apis: []
common:
- type: DomainSecurity
  url: security/grey-wolf-therapeutics-domain-security.yml
- type: Website
  url: https://greywolftherapeutics.com/
- type: Blog
  url: https://greywolftherapeutics.com/latest-news
- type: Support
  url: https://greywolftherapeutics.com/contact-us
- type: PrivacyPolicy
  url: https://greywolftherapeutics.com/privacy-policy
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence